Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported

BMJ. 2022 Apr 26:377:o973. doi: 10.1136/bmj.o973.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cytidine / analogs & derivatives
  • Drug Approval*
  • Humans
  • Hydroxylamines

Substances

  • Hydroxylamines
  • Cytidine
  • molnupiravir